Background {#s1}
==========

Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (*FGFR1*) rearrangement has been presented as an independent disease classification in the 2016 World Health Organization classification of tumors of hematopoietic and lymphoid tissues ([@B1]). Rearrangement of the *FGFR1* gene locus leads to more than 10 fused genes, which code for fusion proteins containing the N-terminal derived from a partner gene and the C-terminal of tyrosine kinase domain from the *FGFR1* gene, which causes constitutive activation of *FGFR1* ([@B2]). The patients with *FGFR1* rearrangement usually initiate with myeloproliferative neoplasm (MPN) and undergo through diverse clinical courses such as lymphoblastic lymphoma (LBL), acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) ([@B3]). Here, we reported an interesting and very rare case which presented sequentially as MPN, T-LBL in lymph nodes and mixed phenotype acute leukemia

(MPAL) in bone marrow. To the best of our knowledge, our case represents the first report of this disease with three distinct developmental phases.

Case Presentation {#s2}
=================

A 37-year-old male patient was admitted to our center in August 2017 due to abnormal complete blood count (CBC) with WBC 34.1^\*^10^9^/L and a hemoglobin (HGB) level of 205 g/L. Further bone marrow (BM) evaluation showed hypercellularity with trilineage growth including prominent granulocytic, erythroid and megakaryocytic proliferation ([Figure 1A](#F1){ref-type="fig"}). Myelofibrosis was absent, also *JAK2 V617F/JAK2 exon 12/MPL/CALR* gene mutations or *BCR/ABL* fusion gene were not identified. The EPO level decreased to 0.82 mIU/ml, thus the clinical diagnosis of polycythemia vera (PV) was made by combining with BM biopsy findings and increased hemoglobin. After treatment of phlebotomy and hydroxyurea, patient\'s CBC dropped back normal.

![**(A)** Morphologic changes of BM smear and biopsy showed trilineage hypercellularity at initial onset. **(B)** Cervical lymph node biopsy with infiltration of T lymphoblasts. **(C)** BM smear showed markedly increased abnormal blasts and BM biopsy showed diffuse hyperplasia of immature cells at leukemic stage. **(D)** Flow cytometry analysis showed three separate clonal populations in BM sample. **(E)** G-banding karyotype of the bone marrow (BM) cells demonstrated the t(8;13)(p11.2;ql2.l); t(l;l4)(q42;q12) and trisomy 21. Arrows show the abnormal chromosomes. FISH analysis of BM cells **(F)** and lymph nodes **(G)** with an FGFR1 break-apart DNA probe revealing FGFR1 rearrangement (the 5\'FGFR1 is labeled green, the 3\'FGFR1 is labeled red).](fonc-09-01304-g0001){#F1}

Three months later, the patient came back to the hospital for bilateral cervical lymphadenopathy with fever and fatigue. Ultrasonographic findings suggest splenomegaly and generalized lymphadenopathy on both sides of the diaphragm. Immunohistochemical staining for cervical lymph node biopsy displayed as diffused abnormal proliferative lymphoblastic cells with CD3(+) TdT(+) CD99(+) CD4(+) Ki67(70%), while few scattered cells were positive for MPO, CD117 and CD8 ([Figure 1B](#F1){ref-type="fig"}). Then, the patient was diagnosed as T-lymphoblastic lymphoma (LBL). The CBC of the patient showed a WBC count of 27.16^\*^10^9^/L and a HGB level of 200 g/L. Intriguingly, bone marrow aspirate revealed hypercellularity with predominant blasts ([Figure 1C](#F1){ref-type="fig"}) and flow cytometry showed three separate clonal populations ([Figure 1D](#F1){ref-type="fig"}): (1) The majority of blasts were cells with ambiguous lineage (P3 group, 41.9%), mainly expressed CD33, CD34, CD13, HLA-DR, CD123; partially expressed CD117, CD22, CD19, CD10, cCD79a, and MPO. (2) The myeloid subset (P6 group, 27.6%) mainly expressed CD33, CD13, HLA-DR, CD123, CD4, CD11c and partially expressed CD14 and CD22. (3) The B-lymphoblast subset (P7 group, 4.2%) mainly expressed CD34, CD19, CD22, CD10, cCD79a, HLA-DR and partially expressed CD33 and CD13. Accordingly, the patient was diagnosed as MPAL. Karyotyping analysis of BM sample illustrated as 47, XY, t(1;14)(q42;q12), t(8;13)(p11.2;q12), +21 \[20\] ([Figure 1E](#F1){ref-type="fig"}) and fluorescence *in situ* hybridization (FISH) analysis using the *FGFR1* break-apart probe confirmed the presence of the *FGFR1* rearrangement in all metaphase cells scored ([Figure 1F](#F1){ref-type="fig"}). Then, next generation sequencing (NGS) assay of 118 commonly mutated genes in hematological disorders (listed in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}) identified the amplifications of *RUNX1, ERG*, and *U2AF1* genes on chromosome 21p. Remarkably, a frame-shift variant of F330fs^\*^\>149 in the *RUNX1* gene and a missense mutation of R2263Q in *NOTCH1* were also detected. However, the NGS assay didn\'t identify any gene mutation using the BM samples collected during the patient\'s first visit. Interestingly, *FGFR1* rearrangement was also detected in 36% (18/50) of cells in lymph node biopsy sample ([Figure 1G](#F1){ref-type="fig"}). Based on the clinical course and laboratory findings, the patient was finally diagnosed as myeloid/lymphoid neoplasm with *FGFR1* rearrangement.

The patient was treated with CHOP and hyper-CVAD chemotherapy. However, complete remission (CR) was not achieved. The patient could not find suitable HLA-matched donor for allogeneic hematopoietic stem cell transplantation (HSCT), and no further treatment were performed. Unfortunately, the patient died 10 months after onset.

Discussion {#s3}
==========

Myeloid/lymphoid neoplasms with *FGFR1* rearrangement, also known as the 8p11 myeloproliferative syndrome (EMS) or stem cell leukemia/lymphoma syndrome (SCLL), is extremely rare with around 100 cases reported until now which represented as MPN or more complicated situations ([@B4], [@B5]). It has been reported that FGFR1 could activate multiple signaling pathways as a receptor tyrosine kinase and constitutive activation of FGFR1 by gene fusion is a critical event in oncogenesis ([@B2], [@B4]). The prognosis of patients were generally poor and HSCT is probably the best choice for a long-term survival ([@B5], [@B6]). The presence of multiple lineage disorders suggests the involvement of stem cells for patients harboring *FGFR1* rearrangement ([@B3]). Gain of an additional copy of chromosome 21 is associated with progression of EMS, but its exact role remains unclear ([@B2]). Here we detected the amplifications of *RUNX1, ERG*, and *U2AF1* genes on chromosome 21p, which have been reported playing important roles in the pathogenesis of hematological malignancies ([@B7], [@B8]). A high frequency of *RUNX1* mutation can be seen in patients with *FGFR1* rearrangement ([@B9]), which have also been detected in a variety of hematological malignancies. Here, we also identified a missense variant of *NOTCH1* and this gene is recurrently found mutated in T-ALL but firstly reported in EMS. While, *RUNX1* and *NOTCH1* mutations were identified in the late stage of the disease (MPAL), but not in the initial stage of the disease (MPN). These findings indicated that FGFR1 rearrangement might be the initial oncogenic event in the hematopoietic pluripotent stem cells, which promote the trilineage hematopoiesis. Then other genetic events such as *RUNX1* and/or *NOTCH1* abnormalities further accelerated the progress of the disease, resulting in acute leukemia with trilineage blasts assignment ([Figure 2](#F2){ref-type="fig"}). The abnormal hematopoietic stem cells present various phenotypes because of distinct microenvironments, such as lymphoma in lymph nodes or leukemia/MPN in bone marrow.

![Schematic diagram of the disease progression mechanism. HSC, hematopoietic stem cells; CMP, conu11on myeloid progenitor; CLP, common lymphoid progenitor; GMP, granulocyte macrophage progenitor; MEP, megakaryocyte erythroid progenitor; Pro-T, T progenitor cells; Pro-B, B progenitor cells.](fonc-09-01304-g0002){#F2}

Conclusion {#s4}
==========

Our case provides a typical clinico-pathogenic model of myeloid/lymphoid neoplasm with *FGFR1* rearrangement, which has not been reported previously. More clinical data are needed to identify the pathogenesis and interaction mechanism as well as optimal therapeutic approach to improve clinical outcomes.
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